Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma

Journal of Korean Medical Science

Volumn 24, Issue 5, 2009, Pages 874-878

  Cho, Eun Hee ^a,b   Lee, Sang Ah ^a   Chung, Ji Youn ^a   Koh, Eun Hee ^a   Cho, Young Hyun ^a   Kim, Jeong Hoon ^a   Kim, Chang Jin ^a   Kim, Min Seon ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Kangwon National University   (South Korea)

Author keywords

Cabergoline; Invasive giant prolactinoma; Male; Prolactin; Tumor size

Indexed keywords

ANTINEOPLASTIC AGENT; CABERGOLINE; ERGOLINE DERIVATIVE; PROLACTIN;

ADULT; ARTICLE; BLOOD; CASE REPORT; HUMAN; HYPOPHYSIS TUMOR; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PROLACTINOMA; RETROSPECTIVE STUDY;

ADULT; ANTINEOPLASTIC AGENTS; ERGOLINES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; RETROSPECTIVE STUDIES;

EID: 75349105917     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2009.24.5.874     Document Type: Article

References (15)

1. Shrivastava RK, Arginteanu MS, King WA, Post KD. Giant prolactinomas: clinical management and long-term follow up. J Neurosurg 2002; 97: 299-306.
2. Shimon I, Benbassat C, Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol 2007; 156: 225-31.
3. Schaller B. Gender-related differences in prolactinomas. A clinicopathological study. Neuro Endocrinol Lett 2005; 26: 152-9.
4. Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, Schoenfelder JR, Klibanski A. Treatment of prolactinse-creting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996; 81: 2338-43.
5. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 1997; 82: 2102-7.
6. Hulting AL, Muhr C, Lundberg PO, Werner S. Prolactinomas in men: clinical characteristics and the effect of bromocriptine treatment. Acta Med Scand 1985; 217: 101-9.
7. Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, Mucci M, Muratori M, Musatti L, Verbessem G, Scanlon MF. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf) 1997; 46: 409-13.
8. Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, Zarrilli S, Lombardi G. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 2004; 89: 1704-11.
9. Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, Colosimo C. Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol (Oxf) 2003; 58: 662-70.
10. Ciccarelli E, Camanni F. Diagnosis and drug therapy of prolactinoma. Drugs 1996; 51: 954-65.
11. Suliman SG, Gurlek A, Byrne JV, Sullivan N, Thanabalasingham G, Cudlip S, Ansorge O, Wass JA. Nonsurgical cerebrospinal fluid rhinorrhea in invasive macroprolactinoma: incidence, radiological, and clinicopathological features. J Clin Endocrinol Metab 2007; 92: 3829-35.
12. Leong KS, Foy PM, Swift AC, Atkin SL, Hadden DR, MacFarlane IA. CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas. Clin Endocrinol (Oxf) 2000; 52: 43-9.
13. Baskin DS, Wilson CB. CSF rhinorrhea after bromocriptine for prolactinoma. N Engl J Med 1982; 306: 178.
14. Serri O, Rasio E, Beauregard H, Hardy J, Somma M. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med 1983; 309: 280-3.
15. Nelson PB, Goodman M, Maroon JC, Martinez AJ, Moossy J, Robinson AG. Factors in predicting outcome from operation in patients with prolactin-secreting pituitary adenomas. Neurosurgery 1983; 13: 634-41.